The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry

Virology

Volumn 244, Issue 2, 1998, Pages 530-541

  Zhang, Jie Lin ^a   Choe, Hyeryun ^b   Dezube, Bruce J ^a   Farzan, Michael ^b   Sharma, Prem L ^a   Zhou, Xiao Chaun ^a   Chen, Lan Bo ^b   Ono, Mitsunori ^c   Gillies, Stephen ^c   Wu, Yaming ^c   Sodroski, Joseph G ^b   Crumpacker, Clyde S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Fuji ImmunoPharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZO COMPOUND; FP 21399; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG RECEPTOR BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; SYNCYTIUM; TARGET CELL; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 17544388251     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9115     Document Type: Article

References (45)

1. Berger E. A., Lifson J. D., Eiden L. E. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: Implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc. Natl. Acad. Sci. USA. 88:1991;8082-8086.
2. Binley J., Moore J. P. HIV-cell fusion: The viral mousetrap. Nature. 387:1997;346-348.
3. Cardin A. D., Smith P. L., Hyde L., Blankenship D. T., Bowlin T. L., Schroeder K., Stauderman K. A., Taylor D. L., Tyms A. S. Stilbene disulfonic acids: CD4 antagonists that block human immunodeficiency virus type-1 growth at multiple stages of the virus life cycle. J. Biol. Chem. 266:1991;13355-13363.
4. Camerini D., Seed B. A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell. 60:1990;747-754.
5. Celada F., Cambiaggi C., Maccari J., Burastero S., Gregory T., Patzer E., Porter J., McDanal C., Matthews T. Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J. Exp. Med. 172:1990;1143-1150.
6. Chan D. C., Fass D., Berger J. M., Kim P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
7. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
8. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
9. De Jong J. J., De Ronde A., Keulen W., Tersmette M., Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J. Virol. 66:1992;6777-6780.
10. Ebenbichler C., Westervelt P., Carrillo A., Henkel T., Johnson D., Ratner L. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations. AIDS. 7:1993;639-646.
11. Farzan M., Choe H., Martin K., Marcon L., Hofmann W., Karlsson G., Sun Y., Barrett P., Marchand N., Sullivan N., Gerard N., Gerard C., Sodroski J. Two orphan seven-transmembrane segment receptors that are expressed in CD4-positive cells support simian immunodeficiency virus infection. J. Exp. Med. 272:1997;6854-6857.
12. Fischer P. B., Karlsson G. B., Butters T. D., Dwek R. A., Platt F. M. N-Butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J. Virol. 70:1996;7143-7152.
13. Fouchier R. A., Groenink M., Kootstra N. A., Tersmette M., Huisman H. G., Miedema F., Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:1992;3183-3187.
14. Gottlinger H. G., Dorfman T., Cohen E. A., Haseltine W. A. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA. 90:1993;7381-7385.
15. Hart T. K., Kirsh R., Ellens H., Sweet R. W., Lambert D. M., Petteway S. R. Jr., Leary J., Bugelski P. J. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 88:1991;2189-2193.
16. Hollinger F. B. ACTG Virology Manual for HIV Laboratories. 1994;NIH, Washington.
17. Klotman M. E., Kim S., Buchbinder A., DeRossi A., Baltimore D., Wong-Staal F. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc. Natl. Acad. Sci. USA. 88:1991;5011-5015.
18. Koito A., Harrowe G., Levy J. A., Cheng-Mayer C. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J. Virol. 68:1994;2253-2259.
19. Kozak S. L., Platt E. J., Madani N., Ferro F. E. Jr., Peden K., Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71:1997;873-882.
20. Lifson J. D., Feinberg M. B., Reyes G. R., Rabin L., Banapour B., Chakrabarti S., Moss B., Wong-Staal F., Steimer K. S., Engleman E. G. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature. 323:1986;725-728.
21. Lifson J. D., Rausch D. M., Kalyanaraman V. S., Hwang K. M., Eiden L. E. Synthetic peptides allow discrimination of structural features of CD4(81-92) important for HIV-1 infection versus HIV-1-induced syncytium formation. AIDS Res. Hum. Retroviruses. 7:1991;521-527.
22. Lu S., Putney S. D., Robinson H. L. Human immunodeficiency virus type 1 entry into T cells: More-rapid escape from an anti-V3 loop than from an antireceptor antibody. J. Virol. 66:1992;2547-2550.
23. Moore J. P., McKeating J. A., Weiss R. A., Sattentau Q. J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 250:1990;1139-1142.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
25. Ono M., Wada Y., Wu Y., Nemori R., Jinbo Y., Wang H., Lo K. M., Yamaguchi N., Brunkhorst B., Otomo H., Wesolowski J., Way J. C., Itoh I., Gillies S., Chen L. B. FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Nature Biotechnol. 15:1997;343-348.
26. Orloff S. L., Kennedy M. S., Belperron A. A., Maddon P. J., McDougal J. S. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 67:1993;1461-1471.
27. Page K. A., Stearns S. M., Littman D. R. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J. Virol. 66:1992;524-533.
28. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
29. Reed J., Kinzel V. Inhibitors of the conformational switch involved in CD4 binding by the env glycoprotein gp120 from human immunodeficiency virus type 1 (HIV1). Biochemistry. 33:1994;10993-10998.
30. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 239:1988;487-491.
31. Sattentau Q. J., Moore J. P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174:1991;407-415.
32. Shioda T., Levy J. A., Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 89:1992;9434-9438.
33. Srivastava K. K., Fernandez-Larsson R., Zinkus D. M., Robinson H. L. Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: Rate and efficiency of entry, a major determinant of permissiveness. J. Virol. 65:1991;3900-3902.
34. Sodroski J., Goh W. C., Rosen C., Campbell K., Haseltine W. A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature. 322:1986;470-474.
35. Stamatatos L., Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:1995;6191-6198.
36. Stein C. A., Neckers L. M., Nair B. C., Mumbauer S., Hoke G., Pal R. Phosphorothioate oligodeoxcytidine interferes with binding of HIV-1 gp120 to CD4. J. Acquir. Immune. Defic. Syndr. 4:1991;686-693.
37. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:1995;4413-4422.
38. Terwilliger E. F., Cohen E. A., Lu Y. C., Sodroski J. G., Haseltine W. A. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. USA. 86:1989;5163-5167.
39. Thali M., Furman C., Helseth E., Repke H., Sodroski J. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J. Virol. 66:1992;5516-5524.
40. Ugolini S., Moulard M., Mondor I., Barois N., Demandolx D., Hoxie J., Brelot A., Alizon M., Davoust J., Sattentau Q. J. HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4. J. Immunol. 159:1997;3000-3008.
41. Weissenhorn W., Dessen A., Harrison S. C., Skehel J. J., Wiley D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430.
42. Weissenhorn W., Wharton S. A., Calder L. J., Earl P. L., Moss B., Aliprandis E., Skehel J. J., Wiley D. C. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 15:1996;1507-1514.
43. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
44. Westervelt P., Trowbridge D. B., Epstein L. G., Blumberg B. M., Li Y., Hahn B. H., Shaw G. M., Price R. W., Ratner L. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J. Virol. 66:1992;2577-2582.
45. Wu L., Gerard N. P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A. A., Desjardin E., Newman W., Gerard C., Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.